



**Evidence for Non-communicable Diseases: analysis of
Cochrane reviews and randomized trials by World Bank
classification**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003298
Article Type:	Research
Date Submitted by the Author:	24-May-2013
Complete List of Authors:	<p>Heneghan, Carl; Oxford University, Primary Health Care Blacklock, Claire; University of Oxford, Department of Primary Health Care Thompson, Matthew; Oxford University, Department of Primary Care Health Sciences Perera, Rafael; University of Oxford, Primary Health Care Davis, Ruth; University of Oxford, Department of Primary Care Health Sciences Banerjee, Amitava; University of Birmingham, Cardiology Gill, Peter; University of Oxford, Primary Care Health Sciences Liew, Su-May; University of Malaya, Department of Primary Care Medicine and Julius Center UM Chamas, Liliane; University of Oxford, OCDEM Hernandez, Jose; University of Oxford, Department of Primary Health Care Mahtani, Kamal; University of Oxford, Primary Care Health Sciences Hayward, Gail; Oxford University, Department of Primary Care Health Sciences Harrison, Sian; University of Oxford, Department of Primary Health Care Lasserson, Daniel; University of Oxford, Department of Primary Health Care; University of Oxford, Primary Care Health Sciences Mickan, Sharon; University of Oxford, Primary Care Health Sciences Sellers, Charlotte; University of Oxford, Primary Care Health Sciences Carnes, Dawn; Barts and The London School of Medicine and Dentistry, Centre for Primary Care and Public Health Homer, Kate; Barts and The London School of Medicine and Dentistry, Centre for Primary Care and Public Health Steed, Liz; Barts and The London School of Medicine and Dentistry, Centre for Primary Care and Public Health Ross, Jack; University of Oxford, Primary Health Care Denny, Nicholas; Oxford University, Medical School Goyder, Clare; University of Oxford, Primary Care Health Sciences Ward, Alison; University of Oxford, Primary Care Health Sciences</p>
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Diabetes and endocrinology, Evidence based practice, Oncology, Medical publishing and peer review, Cardiovascular medicine
Keywords:	EPIDEMIOLGY, ONCOLOGY, NEUROLOGY, DIABETES & ENDOCRINOLOGY, CARDIOLOGY

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SCHOLARONE™
Manuscripts

For peer review only

Evidence for Non-communicable Diseases: analysis of Cochrane reviews and randomized trials by World Bank classification

Heneghan C,¹ Blacklock C,¹ Perera R,¹ Davis R,¹ Banerjee A,² Gill P, Liew S,^{1,3} Chamas L,⁴ Hernandez J,¹ Mahtani K,¹ Hayward G,¹ Harrison S,¹ Lasserson D,¹ Mikan S,¹ Sellers C,¹ Carnes D,⁵ Homer K,⁵ Steed L,⁵ Ross J,⁶ Denny N,⁶ Goyder C,¹ Thompson M,¹ Ward A.¹

¹Department of Primary Care Health Sciences, University of Oxford

²University of Birmingham

³University of Malaya

⁴Oxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford

⁵Centre for Primary Care and Public Health, Barts and The London School of Medicine and Dentistry

⁶Oxford University Medical School

Correspondence to:

Dr Carl Heneghan

Department of Primary Care Health Sciences, Oxford University

2nd Floor, 23-38 Hythe Bridge Street,

Oxford

OX1 2ET

Carl.heneghan@phc.ox.ac.uk

Word count

Abstract: 300

Main article: 3,270

References: 30

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article summary

Article focus

- Non-communicable diseases (NCDs) such as cardiovascular disease, diabetes, chronic respiratory disease and cancer are increasing in prevalence.
- NCDs are set to increase disproportionately in low and middle income countries over the next 20 years
- We aimed to estimate the distribution of evidence relating to NCDs in all Cochrane systematic reviews by country and income distribution.

Key messages

- The overwhelming body of evidence for NCDs relates to high income countries.
- Out of 8,850 trials we found only 13 (0.15%) with 982 (0.01%) participants were undertaken in low income countries.
- Only a small number of review authors were based in low income settings.

Strength and limitations of this study

- In 15% of the reviews we were unable to identify the country of origin for the trial.
- Systematic reviews and trials can only serve as a proxy for high quality evidence and information
- We did not review case-control, cohort studies and reviews published in the grey literature as they do not represent traditional streams of robust evidence

Abstract

Introduction

Prevalence of non-communicable diseases (NCDs) is increasing globally, with the greatest projected increases in low and middle income countries. We sought to quantify the proportion of Cochrane evidence relating to NCDs derived from such countries.

Methods

We searched the Cochrane database of systematic reviews for reviews relating to NCDs highlighted in the WHO NCD action plan (cardiovascular, cancers, diabetes and chronic respiratory diseases). We excluded reviews at protocol stage and those that were repeated or had been withdrawn. For each review two independent researchers extracted data relating to country of corresponding author and the number of trials and participants from countries, using World Bank classification of gross national income per capita.

Results

797 reviews were analysed, with a reported total number of 12,340 trials and 10,937,306 participants. Of the corresponding authors 90% were from high-income countries (41% from the UK). Of the 746 reviews in which at least one trial had met the inclusion criteria, only 55% provided a summary of the country of included trials. Analysis of the 633 reviews in which country of trials could be established revealed that almost 90% of trials and over 80% of participants were from high-income countries. 438 (5.0%) trials including 1,145,013 (11.7%) were done in low-middle income countries. We found only 13 (0.15%) trials with 982 (0.01%) participants were undertaken in low income countries. Other than the five Cochrane NCD corresponding authors from South Africa, only one other corresponding author was from Africa (Gambia).

Discussion

The overwhelming body of evidence for NCDs pertains to high income countries, with only a small number of review authors based in low income settings. As a consequence there is an urgent need for research infrastructure and funding for the undertaking of high quality trials in this area.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Background

The global prevalence of non-communicable diseases (NCDs) such as cardiovascular disease, diabetes, chronic respiratory disease and cancer is increasing (1, 2). Alarming, NCDs are set to increase disproportionately in low and middle income countries over the next 20 years, placing additional burden on already overstretched health systems (1-3). The World Health Organisation estimated that 36 million deaths in 2008 were due to NCDs, of which 9 million were in people younger than 60 years, and 80% of the 36 million deaths occurred in developing countries. (4) In 2010, the World Health Organisation published its ‘Package for essential non-communicable disease interventions for primary health care in low-resource settings,’ to provide a prioritised set of cost-effective interventions to improve equity and efficiency in NCD care. (5) Calls to action from the international community have reported that NCDs present ‘a global crisis and require a global response’. (6) A high-level United Nations meeting took place in September 2011 from which a detailed declaration was made devoted to the prevention and control of NCDs, with particular focus on the challenges faced by developing countries. (4) In addition, attention has been drawn to significant arising issues around inequity, which will impact markedly on effective chronic disease care. (2, 7, 8) For example, effective care requires access to vital medicines for NCDs, such as inhaled steroids in asthma, (9) without which national management strategies become strained, if not impossible.

Systematic reviews provide high quality evidence from which clinical guidelines and public health policy can be developed. However, recognition and evaluation of potential differences between trial population and healthcare population and setting is important when applying such evidence into clinical practice and public health policy. Indeed an intervention, whether non-drug or drug, may ideally have to be trialled in the population that it is intended for. (10, 11) However, in systematic reviews of interventions for NCDs, whether drug or non-drug, there is often no randomized trial evidence from low and middle income countries. (12-14) A number of trials have established effective methods for controlling the key risk factors for globally important NCDs, including reducing blood pressure, cholesterol, smoking. Yet, this evidence may be difficult to apply in low and middle income countries due to lack of generalisability of findings to LMIC settings. (15)

Therefore, to better understand the representation of populations by national income in global trial evidence for interventions for NCDs, and to scope potential gaps, we sought to answer the question: “in which countries are the randomized trials relating to NCDs performed, and how frequently is this reported?” We aimed to estimate the frequency of trial populations by country, included in all

Cochrane systematic reviews relating to NCDs, and the distribution of evidence in these reviews by gross national income (GNI) of trial population.

Methods

We used the 2008-2013 World Health Organisation Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases to define NCDs for this study. (16) This definition included cardiovascular diseases, cancers, diabetes and chronic respiratory diseases. We also chose to include tobacco use, to represent one common and accepted NCD risk factor.

We classified gross national income (GNI) of a country according to the World Bank Classification (**Supplementary Table 1**-correct as of May 2011 <http://data.worldbank.org/about/country-classifications/country-and-lending-groups>): low-income (GNI per capita \$995 or less), lower-middle income (GNI per capita \$996-\$3945), upper-middle income (GNI per capita \$3946-\$12195), high income (GNI per capita \$12196 or above). We included Taiwan as high income in the analysis. We used the May 2011 classification, which is now revised (both classifications shown in **Supplementary Table 1**)

We accessed the online Cochrane Database of Systematic Reviews (<http://www.thecochranelibrary.com>) in May 2011 to identify reviews that related to NCDs, for inclusion in the subsequent data extraction. Identification of reviews for inclusion was performed by a single researcher (CB), with all inclusion and exclusion decisions checked by a second researcher (CH). Reviews were included if the review related to one of the four NCDs: cardiovascular disease, cancer, diabetes, chronic respiratory disease or tobacco use. We firstly identified relevant Cochrane Groups from the overall database. Included and excluded groups are shown in **Supplementary Table 2**. From the included Cochrane disease groups, we included all review categories within the group relating to the pre-defined NCDs, and excluded all other review categories. For each included review category, we excluded all reviews at protocol stage only, and any obvious duplicate reviews.

Each included review and each Cochrane disease group was then coded by a single researcher (CB) to identify: 1) the NCD area (i.e. cardiovascular disease, cancer, diabetes, chronic respiratory disease), and 2) the domain (i.e. prevention, screening, management, diagnosis, other).

We divided included Cochrane reviews into pairs of approximately 50 reviews (total 17 pairs), with electronic links to each review (Microsoft Excel 2007 version). Two researchers independently

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

extracted data onto the standardised Excel spreadsheets. Repeated or withdrawn reviews were coded as such by the researchers and not included in the final analysis.

The following data were extracted from each full text Cochrane review: year of publication, year content assessed up to date, corresponding author details, whether a summary of countries of included trials was provided, year of earliest and latest included trials, total number of included trials and participants (but not age distribution), number of trials and participants from low-income, low-middle income, upper-middle income, mixed income countries, and high income countries. World Bank classification of country by gross national income (GNI) was included on all extraction sheets and was used to classify countries. Where the review did not provide a summary of countries of included trials, the researcher attempted to locate and review individual trial reports of included trials to establish the country in which each trial was conducted. Where only the countries of some trials were reported in the review, a pragmatic decision was made as to whether the review had provided a summary, based on the completeness with which the review reported trial countries. Where data was unobtainable it was recorded as missing. Each researcher was given a standardised instruction pack and spreadsheet for data collection. Queries in the data identified by individual researchers during the data extraction process were resolved by three coordinating researchers (CB, RD, CH), and responses were circulated to all researchers undertaking data extraction.

After data had been extracted in duplicate for each review, a third independent researcher (CB, CH) compared extracted data and constructed a single data sheet for analysis. Where there was disagreement between the first and second researchers, the third researcher checked calculations and if necessary checked data from the appropriate Cochrane review, or the individual trials. If this was not possible, the data was considered unattainable and coded as missing. The third researchers (CB, CH) finally made a joint check of all completed data sheets.

The final data sheets were exported into SPSS software for analysis (IBM SPSS version 19.0). The dataset was first checked for any erroneous data entry by a third researcher (CB, CH) and amended where necessary. Descriptive analyses were used to present frequencies of the number of trials, and the trial populations by location, and StatPlanet (<http://www.statsilk.com/>) software was used to provide a visual world map of frequencies of the location of Cochrane review authors. We used kappa to report agreement between the initial data extraction by the two independent researchers. In our analysis the two independent researchers were recorded as being in agreement if the sum of their data entries for trials (or participants) from each category of GNI for a specific Cochrane review was

exactly the same (i.e. if the recorded number of trials or participants varied at all between the two researchers this was counted as a disagreement).

Results

A total of 797 systematic reviews were included in the study, after exclusion of repeated and withdrawn reviews. Of these we found 51 reviews in which no trials had been identified by the review authors as satisfying the inclusion criteria (**Figure 1**). These were excluded from the final analysis of trial and participant data. Overall, the remaining 746 Cochrane reviews included a total of 12,340 trials involving 10,937,306 participants.

The countries listed by corresponding authors from the 797 identified reviews (including those 51 with no identified trials) are shown in **Figure 2** and **Supplementary Table 2**. Over 90% of the corresponding authors of Cochrane NCD reviews were based in high income countries by World Bank classification (720/797, 90.3%). By far the most frequent country was the UK (n=327, 41%), followed by Australia (77, 9.7%), Canada (61, 7.7%) and the US (54, 6.8%). China and India, both low-middle income countries in May 2011, represented 2.6% (n= 37) and 0.1% (n= 1) respectively of corresponding authors (note: China has since been reclassified as upper-middle income by the World Bank). South Africa, Brazil and Russia, three upper-middle income countries, represented 0.6% (n= 5), 1.5% (n= 12) and 0.1% (n= 1) of corresponding authors respectively. Other than the five Cochrane NCD corresponding authors from South Africa, (17-21) only one other corresponding author was from Africa (Gambia). (22)

The mean number of included trials in the 746 Cochrane reviews which had identified at least one trial for inclusion varied considerably across review groups (**Table 1**). Likewise, the mean number of participants also varied, from a mean of 575 per review (Childhood Cancer group) to 42,256 per review (Gynaecological Cancer group). The average year of review publication ranged from 2007 (Breast Cancer group) to 2011 (Childhood Cancer group).

Table 1:Cochrane NCD reviews included in analysis- table of characteristics

Cochrane group	Cochrane group office	Total reviews analysed	Summary of trial countries n (%)	Country of trials established n (%)	Mean year publication	Mean number of trials per review Mean (SD)	Mean participants per review Mean (SD)
Airways	UK	168	86 (51.2)	138 (82.1)	2009	17.2 (18.3)	3895 (7354)
Breast cancer	Australia	37	22 (59.5)	32 (86.5)	2007	14.4 (14.3)	41663 (160456)
Childhood cancer	Netherlands	8	3 (37.5)	7 (87.5)	2011	7.0 (8.9)	575 (830)
Colorectal cancer	Denmark	34	17 (50.0)	27 (79.4)	2009	13.8 (12.5)	13548 (56984)
ENT disorders	UK	5	2 (40.0)	5 (100)	2009	6.0 (5.8)	1986 (2636)
Gynaecological cancer	UK	83	39 (47.0)	66 (80.0)	2010	13.5 (17.1)	42256 (209079)
Haematological malignancies	Germany	18	4 (22.2)	15 (83.3)	2010	10.9 (11.0)	1943 (2212)
Heart	UK	54	32 (59.3)	46 (85.2)	2009	17.6 (16.3)	13806 (27247)
Hepatobiliary	Denmark	9	7 (77.8)	9 (100)	2009	7.7 (5.9)	24065 (70409)
Hypertension	Canada	30	12 (40)	19 (63.3)	2009	26.1 (30.8)	22779 (42574)
Lung cancer	Spain	22	6 (27.3)	13 (59.1)	2010	15.5 (16.2)	18662 (55633)
Metabolic and endocrine	Germany	34	28 (82.4)	31 (91.2)	2009	27.5 (58.3)	15526 (57729)
Oral health	UK	6	6 (100)	6 (100)	2010	47.7 (51.3)	38431 (75374)
Pain, palliative and supportive care	UK	44	10 (22.7)	29 (65.9)	2010	17.5 (16.6)	1720 (1885)
Prostatic disease and urological cancer	USA	18	7 (38.9)	18 (100)	2010	13.4 (15.5)	23525 (79720)
Stroke	UK	114	78 (68.4)	104 (91.2)	2009	9.5 (8.1)	2823 (6018)
Tobacco addiction	UK	53	46 (86.8)	53 (100)	2009	27.6 (25.5)	24046 (42890)
Upper GI and pancreatic diseases	Canada	9	6 (66.7)	8 (88.9)	2010	13.2 (10.1)	1774 (1658)
Total		746	411 (55.1)	626 (83.9))			

Of the 746 reviews which had included at least one trial, almost half (44.9%) did not provide a summary of trial countries within the review (**Figure 3**). The agreement between the two initial independent researchers as to whether reviews had provided a summary of countries of trials was fair (Kappa 0.65); Reporting of trial countries in the review varied between Cochrane groups, with one group reporting trial countries in 100% of reviews (Oral Health; however only 6 reviews were from this group), and others reporting trial countries in less than a quarter of reviews (Haematological Malignancies 4/18, 22.2%; Pain, Palliative and Supportive Care 10/44, 22.7%). When present, reporting of trial countries was typically identified from the Characteristics of Included Studies table, whereas in others it was summarised in the text of the review.

In two thirds of the 335 reviews that did not summarise countries, we were able to subsequently establish the countries of included trials in two thirds (221/335, 66.0%)(**Figure 1**). These reviews, in addition to the 411 reviews that had provided a summary of trials of countries in the review report, gave a total of 633 reviews for which we were able to determine the number of trials and participants by World Bank GNI category of trial country. Despite provision of a summary, we were unable to confidently establish the countries of all included trials in five reviews- this was mainly due to ambiguous reporting of some trial countries, e.g. 'international', that was could not be resolved by our subsequent methods (these 5 reviews represented 168 (1.4%) trials).

Almost 90% of trials in the analysis ($n = 7,869/8,850$; 88.9%) and over 80% of participants ($8,053,378/9,806,291$; 82.1%) were from high-income countries (**Figure 3**). Low-middle income countries were second most frequently represented, comprising 4.95% of trials ($n = 438$) and 11.68% of participants ($n = 1,145,013$). Least represented were low-income countries, which contributed only 0.15% of trials ($n = 13$) and 0.01% of participants ($n = 982$) overall. All individual Cochrane disease groups except Oral Health and Breast Cancer included the majority of participants from high income countries (**Figure 4**). When analysed by Cochrane disease group, the Heart and Stroke groups had the largest proportion of included trials from lower-middle income countries (13.9% ($n = 92/662$) and 11.8% ($n = 109/928$) respectively). Also notable, was the comparatively low proportion of trials from lower-middle income countries in the Oral Health and Breast Cancer groups; however, despite this these trials contributed a larger proportion to the overall number of participants (84.3% ($n = 194,439/230,584$) and 45.2% ($n = 672,626/1,489,628$) of participants respectively).

Subgroup analysis of the distribution of reviews by type of review mirrored the overall findings above. Once again high income countries were the origin the vast majority of prevention trials (873/942

(92.7%)) and participants (3935969/4204345 (93.6%)) , screening trials (140/143 (97.9%)) and participants (1692826/1885858 (89.8%)) , management trials (6666/7570 (88.1%)) and participants (1819032/2296298 (79.2%)), and 'other' trials (133/135 (98.5%)) and participants (30182/50939 (59.3%)), apart from reviews relating to diagnosis (**Figure 5**). Of the four diagnostic Cochrane reviews: 2 included trials were from low-middle income countries and contributed 671,014 participants (49.0%), a single trial was from an upper-middle income country and contributed 122,468 participants (8.9%), the remaining 57 included trials were from high income countries and contributed 575,369 participants (42.1%).

Discussion

Overall, we found a blatant lack of evidence in low and middle income countries. From 746 systematic reviews of 12,340 trials (10,937, 306 participants), only 13 trials (982 participants) were undertaken in low income countries. The overwhelming body of evidence for NCDs pertains to high income countries, with only a small number of review authors based in low income settings.

In addition, low income countries are poorly represented amongst reviews. For example, other than five review corresponding authors based in South Africa only one further author was based in Africa (the Gambia). The real lack of any Cochrane review authors from many LMICs is surprising. It further reinforces the major developmental gap that is required in engagement and completing research in these settings.

A previous review, published in the New England Journal of Medicine between 1997 and 2004, reported less than 3% of research addressed health issues in the developing world, and the majority of this addressed communicable diseases including HIV. (23) A further review reported >90% of published research by scientists comes from just 20 countries. (24) The gap in scientific publications between low income countries and the rest of the world has widened. (24) Our work suggests this is still the case. This issue has previously been raised by Richard Horton, editor of Lancet, “widespread systematic bias in the medical literature against disease that dominates the least developed regions of the world.” (25)

The question remains as to whether this lack of contextual evidence for LMICs matters? Whilst there has been a dramatic increase in NCDs, particularly in highly populated transition countries, we have shown there is a widespread lack of research into interventions directed to NCD prevention and treatments. (Wagner 2012) The current evidence-base does not relate to the increasing burden of

disease. As a result some interventions (e.g. cancer management) cannot be applied directly to LMICs, often because of the cost of the intervention. Cancer is not mainly confined to the high-resource countries and in the absence of good trial data; often the most appropriate course of action is to modify interventions – according to cost and evidence. This was proposed as early as 1992, by the WHO, which recognised access to cancer services and drugs was limited and likely to worsen. (26)

In addition, many drugs differ in their effects due to ethnic and cultural diversity: b-blockers and ACE inhibitors in hypertension are commonly recognized examples, yet there are certainly many others. Multinational study are often designed, and powered, to detect a single global treatment effect and not to detect subgroup differences that may occur. Yet, systematic differences between treatment effects do occur: often due to variation in genetics, compliance, follow-up, and concomitant medications. (27)

Limitations

A number of limitations in this present study are worth noting. Firstly, in 114/747 of the reviews we were unable to identify the country of origin for the trial. If the majority of trials and participants in these reviews were from LMICs, then our results may look different. In addition, there was some ambiguity in identifying whether or not Cochrane reviews provided details about the country of origin of trials – agreement was judged as only fair. The task required many data extractors, as it was time consuming and it was not helped by how details, or in many cases lack of details, were reported.

Second, systematic reviews and trials can only serve as a proxy for high quality evidence and information; but we did not evaluate the relevance and applicability of the completed trials in low-income countries. We also did not look at the year that each trial was published; therefore we were unable to evaluate the trend in studies being published to determine if the quality of the literature is improving over time. We only included Cochrane reviews and therefore the study does not reflect the entire literature base, but it is a good approximation given the recognized quality of such reviews.

Third, the data we analysed was from previously published Cochrane systematic reviews. There also exist sources of case-control, cohort studies and reviews published in grey literature, the WHOLIS developing country database and ministries of health local papers specific to LMICs. These were not included as they do not represent traditional streams of robust evidence, although they have previously served in developing WHO strategies.

Implication for practice and research

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The study findings raise significant concerns regarding the applicability of the current evidence base for NCDs to LMICs. Certain topics now have reasonable evidence to support them but most have a paucity of contextual trial data. There exists a major issue over the clarity of published papers and systematic reviews. This is an easy issue to fix. New Cochrane systematic review guidelines should require that a breakdown of population and trial countries be disclosed.

There is an obvious, urgent need for more research in low income and low-middle income countries. The practicalities of funding and organising clinical trials in such varied circumstances are likely to be very difficult; but, this should not act as a barrier. Many LMIC healthcare systems are severely underdeveloped with limited or no data collection and similarly limited experience of data collection/running clinical trials. There is therefore a need to develop infrastructure and capacity at a local level.

The high morbidity and mortality from infectious diseases have historically crippled LMICs. The epidemiological transition from infectious to chronic diseases is “more compressed in a shorter timeframe than high incomes,” which explains the lagging gap in evidence. (28) Yet, of research that is published in LMICs journals around 40% focused on NCDs, suggesting that even given the focus on infectious disease research, capability exists to conduct such research. (29) This research is often not translated into systematic reviews or bigger trials because of economic constraints, language barriers and absence of some LMICs journals from MEDLINE. (28)

Part of the WHO Action Plan for the Global Strategy for the Prevention and Control of Non-Communicable Diseases is to respond to the epidemic by integrating disease prevention and control into local policies, and promoting research. (16) But, the medical information gap between rich and poor countries appears to be larger than the gap in funding for research. (23) Commercial efforts are too often focused on where the money is – in providing end products to health professionals. (30) As a consequence many interventions will therefore require funding by non-commercial entities.

Conclusions -

Scant attention has been paid to NCD research in LMICs. Even the research done is often within urban relatively high income settings within a given country. (15) As a consequence there is an urgent need for research infrastructure and the undertaking of high quality trials,

Acknowledgments

Dr Carl Heneghan is supported by the National Institute for Health Research School for Primary Care Research. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Contributions

All authors contributed to the data extraction, CB and CH designed the protocol and the methods and CB CH and RP undertook the data analysis. All authors contributed to the draft of the article and approved the final manuscript. CH is the guarantor of the data.

Conflict of interest

The authors report they have no conflict of interest

Data sharing

No additional data available

References

1. Allotey P, Reidpath DD, Yasin S, et al. Rethinking health-care systems: a focus on chronicity. *Lancet*. 2011 Feb 5;377(9764):450-1.
2. Boutayeb A, Boutayeb S. The burden of non communicable diseases in developing countries. *Int J Equity Health*. 2005 Jan 14;4(1):2.
3. Daar AS, Singer PA, Persad DL, et al. Grand challenges in chronic non-communicable diseases. *Nature*. 2007 Nov 22;450(7169):494-6.
4. United Nations General Assembly. Political declaration of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases. 49777(September), 1-13. 2011.
5. World Health Organisation. (2010). Package of essential noncommunicable (PEN) disease interventions for primary health care in low-resource settings. Geneva: World Health Organization. Retrieved from [http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Package+of+Essential+Noncommunicable+\(+PEN+\)+Disease+Interventions+for+Primary+Health+Care+in+Low-Resource+Settings#0](http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Package+of+Essential+Noncommunicable+(+PEN+)+Disease+Interventions+for+Primary+Health+Care+in+Low-Resource+Settings#0).
6. Beaglehole R, Bonita R, Alleyne G, et al. UN High-Level Meeting on Non-Communicable Diseases: addressing four questions. *Lancet*. 2011 Jul 30;378(9789):449-55.

7. Alwan A, Maclean DR, Riley LM, et al. Monitoring and surveillance of chronic non-communicable diseases: progress and capacity in high-burden countries. *Lancet*. 2010 Nov 27;376(9755):1861-8.

8. Geneau R, Stuckler D, Stachenko S, et al. Raising the priority of preventing chronic diseases: a political process. *Lancet*. 2010 Nov 13;376(9753):1689-98.

9. Ait-Khaled N, Enarson DA, Bissell K, et al. Access to inhaled corticosteroids is key to improving quality of care for asthma in developing countries. *Allergy*. 2007 Mar;62(3):230-6.

10. O'Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. *Clin Cancer Res*. 2009 Aug 1;15(15):4806-14.

11. Opie LH, Seedat YK. Hypertension in sub-Saharan African populations. *Circulation*. 2005 Dec 6;112(23):3562-8.

12. Gaziano TA. Reducing the growing burden of cardiovascular disease in the developing world. *Health Aff (Millwood)*. 2007 Jan-Feb;26(1):13-24.

13. Heneghan C, Ward A, Perera R, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. *Lancet*. 2012 Jan 28;379(9813):322-34.

14. Lim SS, Gaziano TA, Gakidou E, et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. *Lancet*. 2007 Dec 15;370(9604):2054-62.

15. Miranda JJ, Kinra S, Casas JP, et al. Non-communicable diseases in low- and middle-income countries: context, determinants and health policy. *Trop Med Int Health*. 2008 Oct;13(10):1225-34.

16. World Health Organisation. (2013). 2008-2013 Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases The six objectives of the 2008-2013 Action Plan are□:.

17. Cilliers AM, Manyemba J, Saloojee H. Anti-inflammatory treatment for carditis in acute rheumatic fever. *Cochrane Database Syst Rev*. 2003(2):CD003176.

18. Manyemba J, Mayosi BM. Penicillin for secondary prevention of rheumatic fever. *Cochrane Database Syst Rev*. 2002(3):CD002227.

19. Mash B, Bheekie A, Jones PW. Inhaled vs oral steroids for adults with chronic asthma. *Cochrane Database Syst Rev*. 2001(1):CD002160.

20. Rogers L, Siu SS, Luesley D, et al. Adjuvant radiotherapy and chemoradiation after surgery for cervical cancer. *Cochrane Database Syst Rev*. 2009(4):CD007583.

21. Wiysonge CS, Bradley HA, Volmink J, et al. Beta-blockers for hypertension. *Cochrane Database Syst Rev*. 2012;8:CD002003.

22. Okebe JU, Lasserson TJ, Meremikwu MM, et al. Therapeutic interventions for Burkitt's lymphoma in children. *Cochrane Database Syst Rev*. 2006(4):CD005198.

23. Lown B, Banerjee A. The developing world in The New England Journal of Medicine. *Global Health*. 2006;2:3.
24. Paraje G, Sadana R, Karam G. Public health. Increasing international gaps in health-related publications. *Science*. 2005 May 13;308(5724):959-60.
25. Horton R. Medical journals: evidence of bias against the diseases of poverty. *Lancet*. 2003 Mar 1;361(9359):712-3.
26. Wagner KH, Brath H. A global view on the development of non communicable diseases. *Prev Med*. 2012 May;54 Suppl:S38-41.
27. Lawrence J, Bai S, Hung HM, et al. Regional treatment effects in studies of cardiorenal drugs: a summary of recent clinical trials. *J Am Coll Cardiol*. 2012 Sep 18;60(12):1117-8.
28. Mendis S, Yach D, Bengoa R, et al. Research gap in cardiovascular disease in developing countries. *Lancet*. 2003 Jun 28;361(9376):2246-7.
29. Hofman K, Ryce A, Prudhomme W, et al. Reporting of non-communicable disease research in low- and middle-income countries: a pilot bibliometric analysis. *J Med Libr Assoc*. 2006 Oct;94(4):415-20.
30. Godlee F, Pakenham-Walsh N, Ncayiyana D, et al. Can we achieve health information for all by 2015? *Lancet*. 2004 Jul 17-23;364(9430):295-300.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Web Table 1 Gross National Income per capita- World Bank Classification (as correct May 2011)

Subsequent changes to classification shown in *italics (new 2012 category in brackets)*. In addition, new GNI ranges given in *(brackets)*.

Low income	Lower middle income		Upper middle income		High income	
GNI per capita \$995 or less (\$1,005 or less)	GNI per capita \$996- \$3,945 (\$1,006- \$3,975)		GNI per capita \$3946- \$12,195 (\$3,976- \$12,275)		GNI per capita \$12,196 or more (\$12,276 or more)	
Afghanistan	Angola	Paraguay	Albania	Panama	Andorra	Japan
Bangladesh	Armenia	Philippines	Algeria	Peru	Aruba	Korea, Rep.
Benin	Belize	Samoa	American Samoa	Romania	Australia	Kuwait
Burkina Faso	Bhutan	São Tomé and Príncipe	Antigua and Barbuda	Russian Federation	Austria	<u>Latvia (UM)</u>
Burundi	Bolivia	Senegal	Argentina	Serbia	Bahamas, The	Liechtenstein
Cambodia	Cameroon	Sri Lanka	Azerbaijan	Seychelles	Bahrain	Luxembourg
Central African Republic	Cape Verde	Sudan	Belarus	South Africa	Barbados	Macao SAR, China
Chad	<u>China (UM)</u>	Swaziland	Bosnia and Herzegovina	St. Kitts and Nevis	Belgium	Malta
Comoros	Congo, Rep.	Syrian Arab Republic	Botswana	St. Lucia	Bermuda	Monaco
Congo, Dem. Rep	Côte d'Ivoire	<u>Thailand (UM)</u>	Brazil	St. Vincent and the	Brunei Darussalam	Netherlands
Eritrea	Djibouti	Timor-Leste	Bulgaria	Grenadines	Canada	<i>Netherlands Antilles</i>
Ethiopia	<u>Ecuador (UM)</u>	Tonga	Chile	Suriname	Cayman Islands	<i>(no longer listed)</i>
Gambia, The	Egypt, Arab Rep.	<u>Tunisia (UM)</u>	Colombia	Turkey	Channel Islands	New Caledonia
<u>Ghana (LM)</u>	El Salvador	Turkmenistan	Costa Rica	Uruguay	Croatia	New Zealand
Guinea	Georgia	Tuvalu	Cuba	Venezuela, RB	Cyprus	Northern Mariana
Guinea-Bissau	Guatemala	Ukraine	Dominica		Czech Republic	Islands
Haiti	Guyana	Uzbekistan	Dominican Republic		Denmark	Norway
Kenya	Honduras	Vanuatu	<u>Fiji</u>		Estonia	Oman
Korea, Dem Rep.	Indonesia	Vietnam	Gabon		Equatorial Guinea	Poland
Kyrgyz Republic	India	West Bank and Gaza	Grenada		Faeroe Islands	Portugal
<u>Lao PDR (LM)</u>	Iraq	Yemen, Rep.	Iran, Islamic Rep.		Finland	Puerto Rico
Liberia	<u>Jordan (UM)</u>		Jamaica		France	Qatar
Madagascar	Kiribati		Kazakhstan		French Polynesia	San Marino
Malawi	Kosovo		Lebanon		Germany	Saudi Arabia
Mali	Lesotho		Libya		Gibraltar	Singapore
<u>Mauritania (LM)</u>	<u>Maldives (UM)</u>		Lithuania		Greece	Slovak Republic
Mozambique	Marshall Islands		Macedonia, FYR		Greenland	Slovenia
Myanmar	Micronesia, Fed. Sts.		Malaysia		Guam	Spain
Nepal	Moldova		Mauritius		Hong Kong SAR,	Sweden
Niger	Mongolia		Mayotte		China	Switzerland
Rwanda	Morocco		Mexico		Hungary	Trinidad and Tobago
Sierra Leone	Nicaragua		Montenegro		Iceland	Turks and Caicos
<u>Solomon Islands (LM)</u>	Nigeria		Namibia		Ireland	Islands
Somalia	Pakistan		Palau		Isle of Man	United Arab Emirates
Tajikistan	Papua New Guinea				Israel	United Kingdom
Tanzania					Italy	United States
Togo						Virgin Islands (U.S.)
Uganda						<u>Curacao (HI)</u>
<u>Zambia (LM)</u>						<u>Sint Maarten (HI)</u>
Zimbabwe						

Web Table 2 Included and Excluded Cochrane disease groups

Included Cochrane Groups (18)	Excluded Cochrane Groups (44)
Airways	Acute respiratory infection
Breast cancer	Anaesthesia
Colorectal cancer	Back
Childhood cancer	Bone, joint and muscle trauma
Ear nose and throat disorders	Campbell and Cochrane equity methods
Gynaecological cancer	Child Health
Haematological malignancies	Comparing multiple interventions methods
Heart	Complementary medicine
Hepatobiliary	Consumers and communication
Hypertension	Cystic fibrosis and genetic disorders
Lung cancer	Dementia and cognitive improvement
Metabolic and endocrine	Depressions, anxiety and neurosis
Oral health	Developmental psychosocial and learning problems
Pain, palliative and supportive care	Drugs and alcohol
Prostatic disease and urologic cancers	Effective practice and organization of care
Stroke	Epilepsy
Tobacco group	Eyes and vision
Upper gastrointestinal and pancreatic diseases	Fertility regulation
	Health care of older people
	HIV/ AIDS
	Incontinence
	Infectious diseases
	Inflammatory bowel disease and functional bowel disorders
	Injuries
	Menstrual disorders and subfertility
	Methodology
	Movement disorders
	Multiple Sclerosis
	Musculoskeletal
	Neonatal
	Neurological
	Neuromuscular disease
	Non-randomised studies methods
	Nursing care
	Occupational safety and health
	Peripheral vascular diseases
	Pregnancy and childbirth
	Primary health care
	Public health
	Renal
	Schizophrenia
	Sexually transmitted diseases
	Skin
	Wounds

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Web Table 3: Country of corresponding author of 797 Cochrane NCD reviews

Country of corresponding Cochrane author	Number of included reviews (n)	Proportion of included reviews (%)
Argentina	7	.9
Australia	77	9.7
Austria	5	.6
Bahrain	1	.1
Belgium	1	.1
Brazil	12	1.5
Canada	61	7.7
Chile	1	.1
China	37	4.6
Columbia	2	.3
Costa Rica	1	.1
Cuba	1	.1
Denmark	17	2.1
France	4	.5
Gambia	1	.1
Germany	31	3.9
Hong Kong	2	.3
Hungary	2	.3
India	1	.1
Iran	2	.3
Ireland	11	1.4
Israel	9	1.1
Italy	21	2.6
Japan	2	.3
Malaysia	2	.3
Netherlands	40	5.0
New Zealand	14	1.8
Norway	4	.5
Pakistan	2	.3
Poland	1	.1
Portugal	1	.1
Russia	1	.1
Singapore	3	.4
South Africa	5	.6
South Korea	1	.1
Spain	15	1.9
Sweden	2	.3
Switzerland	8	1.0
Taiwan	1	.1
Thailand	3	.4
Turkey	1	.1
UK	327	41.0
Uruguay	2	.3
USA	54	6.8
Venezuela	1	.1

For peer review only

Web Figure 1: Trials and participants from 626 Cochrane NCD reviews by gross national income of trial country, by Cochrane disease group

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42






Figure 1: Proportion of included reviews that reported country of trials, and in which country of trials could be established




124x90mm (300 x 300 DPI)

Figure 2: World Map of location of Cochrane NCD Authors N=797 (219 countries)



133x90mm (300 x 300 DPI)

Figure 3: Trials and number of participants from 626 Cochrane NCD reviews, by Gross National Income (GNI)



123x90mm (300 x 300 DPI)